Disparities in Influenza, Pneumococcal, COVID-19 Vaccine Coverage in High-Risk Adults Aged 19 to 64 Years in Southeastern Minnesota, 2010-2021

被引:3
|
作者
Felzer, Jamie R. [1 ]
Montgomery, Amy J. [2 ]
Lemahieu, Allison M. [3 ]
Rutten, Lila J. Finney [4 ]
Juhn, Young J. [5 ,6 ]
Wi, Chung-Il [5 ,6 ]
Jacobson, Robert M. [4 ,5 ,6 ,7 ]
Kennedy, Cassie C. [1 ,8 ,9 ]
机构
[1] Mayo Clin, Div Pulm & Crit Care, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Med, Rochester, MN USA
[3] Mayo Clin, Div Clin Trials & Biostat, Rochester, MN USA
[4] Mayo Clin, Div Epidemiol, Rochester, MN USA
[5] Mayo Clin, Dept Quantitat Hlth Sci, Div Community Pediat Med, Rochester, MN USA
[6] Mayo Clin, Dept Quantitat Hlth Sci, Div Adolescent Med, Rochester, MN USA
[7] Mayo Clin, Div Pediat Infect Dis, Rochester, MN USA
[8] Mayo Clin, Dept Pediat & Adolescent Med, Div Hlth Care Delivery Res, Rochester, MN 55905 USA
[9] Mayo Clin, Resp Hlth Equ Clin Res Lab, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
adult; health care disparities; respiratory tract infections; risk factors; sociodemographic factors; vaccines; MEDICAL-RECORDS-LINKAGE; DATA RESOURCE PROFILE; ADVISORY-COMMITTEE; CONJUGATE VACCINE; UNITED-STATES; SOCIOECONOMIC-STATUS; UPDATED RECOMMENDATIONS; POLYSACCHARIDE VACCINE; DISEASE; HEALTH;
D O I
10.1016/j.chest.2024.01.049
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Despite effective vaccines against in fl uenza, pneumococcus, and COVID-19, uptake has been suboptimal. RESEARCH QUESTION: Although disparities in vaccination by race and ethnicity have been observed, what is the role of other sociodemographic factors in US vaccine uptake? STUDY DESIGN AND METHODS: We conducted a population-based study using the Rochester Epidemiology Project (REP), a comprehensive medical records linkage system, to assess effects of sociodemographic factors including race, ethnicity, individual-level socioeconomic status (SES) via the housing-based socioeconomic status index, education, population density (urban or nonurban), and marital status with uptake of in fl uenza, pneumococcal, and COVID-19 vaccination in high-risk adults. Adults at high risk of invasive pneumococcal disease residing in four counties in southeastern Minnesota who were aged 19 to 64 years were identi fi ed. Vaccination data were obtained from the Minnesota Immunization Information Connection and REP from January 1, 2010, through December 31, 2021. RESULTS: We identi fi ed 45,755 residents. Most were White (82%), non-Hispanic (94%), married (56%), and living in an urban setting (81%), with three-quarters obtaining at least some college education (74%). Although 45.1% were up to date on pneumococcal vaccines, 60.1% had completed the primary COVID-19 series. For in fl uenza and COVID-19, higher SES, living in an urban setting, older age, and higher education positively correlated with vaccination. Magnitude of differences in race, education, and SES widened with booster vaccines. INTERPRETATION: This high-risk population is undervaccinated against preventable respiratory diseases, especially in fl uenza and pneumococcus. Although national data reported improvement of disparities in COVID-19 vaccination uptake observed early in the pandemic, our data demonstrated gaps related to race, education level, SES, and age that widened with booster vaccines. Communities with high social vulnerabilities often show increased risk of severe disease outcomes, yet demonstrate lower uptake of preventive services. This highlights the need to understand better vaccine compliance and access in rural, lower SES, lesseducated, Black, Hispanic, and younger populations, each of which were associated independently with decreased vaccination. CHEST 2024; 166(1):49-60
引用
收藏
页码:49 / 60
页数:12
相关论文
共 32 条
  • [21] Factors Associated With Willingness to Receive a COVID-19 Vaccine Among 23,819 Adults Aged 50 Years or Older: An Analysis of the Canadian Longitudinal Study on Aging
    Basta, Nicole E.
    Sohel, Nazmul
    Sulis, Giorgia
    Wolfson, Christina
    Maimon, Geva
    Griffith, Lauren E.
    Kirkland, Susan
    McMillan, Jacqueline M.
    Thompson, Mary
    Raina, Parminder
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2022, 191 (06) : 987 - 998
  • [22] COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022
    Soares, Patricia
    Machado, Ausenda
    Nicolay, Nathalie
    Monge, Susana
    Sacco, Chiara
    Hansen, Christian Holm
    Meijerink, Hinta
    Martinez-Baz, Ivan
    Schmitz, Susanne
    Humphreys, James
    Fabiani, Massimo
    Echeverria, Aitziber
    Alkerwi, Ala'a
    Nardone, Anthony
    Mateo-Urdiales, Alberto
    Castilla, Jesus
    Kissling, Esther
    Nunes, Baltazar
    EUROSURVEILLANCE, 2025, 30 (08)
  • [23] Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old
    -Patrick, David Fitz
    Young, Mariano
    Yacisin, Kari
    McElwee, Kathleen
    Belanger, Todd
    Belanger, Kelly
    Peng, Yahong
    Lee, Dung -Yang
    Gruber, William C.
    Scott, Daniel A.
    Watson, Wendy
    VACCINE, 2023, 41 (28) : 4190 - 4198
  • [24] Evaluation of COVID-19 vaccine effectiveness in different high-risk facility types during a period of Delta variant dominance in the Republic of Korea: a cross-sectional study
    Lee, Min Jei
    Hwang, Myung-Jae
    Kim, Dong Seob
    Park, Seon Kyeong
    Choi, Jihyun
    Lee, Ji Joo
    Kim, Jong Mu
    Kim, Young-Man
    Park, Young-Joon
    Gwack, Jin
    Lee, Sang-Eun
    OSONG PUBLIC HEALTH AND RESEARCH PERSPECTIVES, 2023, 14 (05) : 418 - 426
  • [25] Cognitive and emotional factors related to COVID-19 among high-risk ethnically diverse adults at the onset of the New York City outbreak: A cross-sectional survey
    Kukafka, Rita
    Millery, Mari
    Pan, Samuel
    Silverman, Thomas B.
    Zhang, Tianmai
    McGuinness, Julia E.
    Crew, Katherine D.
    Aguirre, Alejandra N.
    HUMANITIES & SOCIAL SCIENCES COMMUNICATIONS, 2023, 10 (01):
  • [26] Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis
    Nagano, Mitsuhiro
    Tanabe, Kosuke
    Kamei, Kazumasa
    Lim, Sooyeol
    Nakamura, Honoka
    Ito, Shuhei
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (10) : 2155 - 2177
  • [27] RETRACTED: Mental health burden for the public affected by the COVID-19 outbreak in China: Who will be the high-risk group? (Retracted article. See vol. 26, pg. 656, 2021)
    Huang, Yeen
    Zhao, Ning
    PSYCHOLOGY HEALTH & MEDICINE, 2021, 26 (01) : 23 - 34
  • [28] Long-term impact of the COVID-19 pandemic on self-management of chronic conditions among high-risk adults in the USA: protocol for the C3 observational cohort study
    Lovett, Rebecca
    Filec, Sarah
    Bonham, Morgan
    Benavente, Julia Yoshino
    O'Conor, Rachel
    Russell, Andrea
    Zheng, Pauline
    Wismer, Guisselle
    Yoon, Esther
    Weiner-Light, Sophia
    Vogeley, Abigail
    Kwasny, Mary Morrissey
    Lowe, Sarah
    Curtis, Laura M.
    Federman, Alex
    Bailey, Stacy C.
    Wolf, Michael
    BMJ OPEN, 2023, 13 (10):
  • [29] Risk Factors for Death Among Hospitalized Patients Aged 21-64 Years Diagnosed with COVID-19-New York City, March 13-April 9, 2020 (Aug, 10.1007/s40615-021-01098-1, 2021)
    Bushman, Dena
    Davidson, Alexander
    Pathela, Preeti
    Greene, Sharon K.
    Weiss, Don
    Reddy, Vasudha
    Latash, Julia
    JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2022, 9 (04) : 1600 - 1600
  • [30] Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged ≥ 12 years, United States, August 2021-October 2022
    Meng, Lu
    Harris, Latreace
    Shaw, Lauren
    Lymon, Hoody
    Reses, Hannah
    Bell, Jeneita
    Lu, Peng -Jun
    Gibbs-Scharf, Lynn
    Chorba, Terence
    VACCINE, 2024, 42 (09) : 2122 - 2126